Research Repository UCD

Title	Liposomal gene delivery mediated by tissue-engineered scaffolds
Authors(s)	Kulkarni, Mangesh, Greiser, Udo, O'Brien, Timothy, et al.
Publication date	2010-01
Publication information	Kulkarni, Mangesh, Udo Greiser, Timothy O'Brien, and et al. "Liposomal Gene Delivery Mediated by Tissue-Engineered Scaffolds" 28, no. 1 (January, 2010).
Publisher	Elsevier
Item record/more information	http://hdl.handle.net/10197/5009
Publisher's statement	This is the author's version of a work that was accepted for publication in Trends in Biotechnology. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Trends in Biotechnology (28, 1, (2010)) DOI: http://dx.doi.org/10.1016/j.tibtech.2009.10.003
Publisher's version (DOI)	10.1016/j.tibtech.2009.10.003

Downloaded 2023-04-07T10:52:29Z

The UCD community has made this article openly available. Please share how this access benefits you. Your story matters! (@ucd_oa)

© Some rights reserved. For more information

Manuscript Number: TIBTECH-D-09-00124R2

Title: Liposomal Gene Delivery Mediated by Tissue-Engineered Scaffolds

Article Type: Review

Corresponding Author: Prof Abhay Pandit,

Corresponding Author's Institution:

First Author: Mangesh Kulkarni

Order of Authors: Mangesh Kulkarni; Udo Greiser; Timothy O'Brien; Abhay Pandit

Abstract: In the absence of a single ideal gene delivery carrier even with the recent explosion of newer ones, the recent trend is to explore the complementary synergy promised by the combination of delivery systems such as the liposomes; the most widely researched versatile non-viral carriers and tissue-engineered scaffolds; the macrostructures with defined architecture comprised of natural or synthetic macromolecules. Here, we discuss the recent advances in liposomal gene delivery and the benefits of the combined liposome-scaffold approach such as long-term expression, enhanced stability, reduction in toxicity and ability to produce spatio-temporal expression patterns. This approach is generating significant impact in the field due to its potential for enhanced extended localised gene delivery for application in a variety of clinical conditions.

1 **Liposomal gene delivery mediated by tissue-engineered scaffolds**

2 **Mangesh Kulkarni¹, Udo Greiser², Timothy O'Brien²**

3 **and Abhay Pandit^{1*}**

4 ¹Network of Excellence for Functional Biomaterials

5 ²Regenerative Medicine Institute

6 National University of Ireland, Galway, Ireland

7 **Addresses:**

8 Mangesh Kulkarni

9 Network of Excellence for Functional Biomaterials

10 NFB Building, IDA Business Park

11 Newcastle Road, Dangan,

12 National University of Ireland, Galway, Ireland

13 Tel. No: +353 91 495833

14 Fax No: + 353 91 495585

15 E-mail address: m.kulkarni1@nuigalway.ie

16

17 Udo Greiser

18 Regenerative Medicine Institute, National Centre for Biomedical Engineering Sciences &

19 Department of Medicine, Orbsen Building, University Road, National University of

20 Ireland, Galway, Ireland

21 Tel. No: + 353 91 495166

22 Fax No: + 353 91 495585

23 E-mail address: udo.greiser@nuigalway.ie

1 Timothy O'Brien
2 Regenerative Medicine Institute, National Centre for Biomedical Engineering Sciences &
3 Department of Medicine, Orbsen Building, University Road, National University of
4 Ireland, Galway, Ireland
5 Tel. No: +353 91 495107
6 Fax No: + 353 91 495585
7 E-mail: timothy.obrien@nuigalway.ie

8

9 Abhay Pandit
10 Network of Excellence for Functional Biomaterials
11 NFB Building, IDA Business Park
12 Newcastle Road, Dangan
13 National University of Ireland, Galway, Ireland
14 Tel. No: +353 91 492758
15 Fax No: + 353 91 495585
16 E-mail address: abhay.pandit@nuigalway.ie

17

18 * Corresponding Author: abhay.pandit@nuigalway.ie

19

20

21

22

23

1 **Abstract**

2 In the absence of any ideal gene delivery carrier despite the recent explosion of novel
3 carrier systems, the current trend is to explore the complementary synergy promised by a
4 combination of delivery systems such as liposomes, which are the most widely
5 researched versatile non-viral carriers and tissue-engineered scaffolds with
6 macrostructures of defined architecture comprised of natural or synthetic macromolecules.
7 Here, we discuss the recent advances in liposomal gene delivery and the possible benefits
8 of a combined liposome-scaffold approach, such as long-term expression, enhanced
9 stability, reduction in toxicity and ability to produce spatio-temporal expression patterns.
10 This approach is generating significant impact in the field due to its potential for
11 extended localised gene delivery for applications in a variety of clinical conditions.

12

13

14 **Gene Delivery Systems**

15 The bottleneck in the success of gene therapy has been the development of a safe and
16 efficient gene delivery system¹. Viral carriers are on one end of the spectrum, with very
17 high transfection efficiency, but also the potential risks of toxicity or immunogenicity, in
18 addition to their other disadvantages, such as difficulty of large scale production and
19 limited capacity to carry DNA beyond a certain size. Naked plasmid DNA is on the other
20 end of the spectrum, exhibiting a very attractive safety profile, but extremely low
21 efficiency. Non-viral carriers, which include liposomes and polymers, lie in middle of the
22 spectrum with a moderate efficiency and safety profile. Research in the field of delivery
23 systems over the past few decades has focused mainly on the development of an optimal

1 delivery system, aiming to increase transfection efficiency towards the viral end of the
2 spectrum, while reducing toxicity to exhibit a superior safety profile and reduce
3 immunological concerns. This review focuses on non-viral carriers, which due to their
4 superior safety profile and their broad acceptance have been considered as reliable
5 treatment options for a wide variety of medical indications and we will provide a
6 snapshot of the versatility of liposomes as the most widely researched non-viral carriers.
7 We will also highlight recent progress in the field, including crucial modifications to the
8 liposomal formulations, which have enabled them to overcome major barriers in systemic
9 delivery or intracellular obstacles to improve their efficiency of gene delivery.

11 Another focus of this review is tissue-engineered scaffolds. These are being widely used
12 as control release systems to deliver drugs, cells and/or bioactive agents, such as growth
13 factors and genes. These slow-release systems can lengthen gene expression without risk
14 of insertional mutagenesis as is the case in some of the viral carriers. However, the
15 delivery of plasmid DNA from tissue-engineered scaffolds still poses the problem of low
16 efficiency. Given the lack of a single superior delivery system that addresses all clinical
17 requirements with high efficacy and a convincing safety profile, an increasing amount of
18 research in recent years has focused on improving the delivery systems through a
19 combinatorial approach, whereby each component complements the others and thus
20 might lead to an optimized outcome.

22 In conclusion, we will illustrate how the combinatorial approach of using liposomal
23 systems together with tissue-engineered scaffolds has been employed and has lead to

1 synergistic effects in three main areas of safety, efficiency and extended expression in a
2 variety of applications and highlight future trends and the promising potential for clinical
3 translation.

4 **Liposomes: multifaceted and versatile non-viral delivery systems**

6 Liposomes are spherical lipid bilayers of diameters in the range of 50–1000 nm that have
7 proven useful as convenient delivery vehicles for biologically active compounds².

8 Liposomal systems, despite being the oldest of the non-viral gene-delivery vehicles, still
9 remain attractive amid a surge of newer non-viral gene carriers. Their persisting
10 popularity is not only due to advantages, such as their unlimited load carrying capacity,
11 relative safety and ease of large-scale production, but can also be attributed to their
12 versatile nature in terms of possible functionalization and formulations. Despite the lower
13 transfection rates of conventional liposomal systems (typically requiring 1,000 to 10,000
14 times more particles to achieve successful genetic modification of cells compared with
15 viral counterparts), their potential for targeted delivery through functionalisation, for
16 example by conjugation with antibody (or fragments), peptides, sugars and so-called
17 ‘stealth’ i.e. polyethylene glycol (PEG)-ylation of lipids, and for escape from the
18 reticuloendothelial system (RES) and, consequently, long-term circulation has proven to
19 be a great advantage. Early progress during the 1970s and 1980s has lead to the
20 development of “stealth” liposomes with long circulation times after intravenous
21 administration and decreased uptake by macrophages. These stealth liposomes are able to
22 extravasate out of vasculature and to accumulate in other target tissues, such as lung,
23 kidney and liver, in therapeutically effective doses without rapid clearance from the

1 blood stream, thus improving their bio-distribution³. Moreover, liposomes can be labeled
2 with fluorescent tags for traceability *in vivo*. A variety of stimuli, such as pH, temperature,
3 ultrasonic waves, magnetic fields and light are currently being investigated for improved
4 gene delivery in various settings⁴⁻⁷. In Tables 1 and 2, we list only the recent, major
5 advances in gene delivery applications (for more extensive and complete versions, the
6 readers are referred to the online supplementary material). Co-application of liposomes
7 with other polymers such as polyethyleneimine provides an avenue for improved
8 transfection efficiency⁸⁻¹⁰.

9

10 *Successful liposomal gene delivery: stumbling blocks and solutions*

11 There are a number of extracellular and intracellular barriers to successful non-viral gene
12 delivery. In systemic delivery, serum instability and sequestration by the RES due to
13 uptake by macrophages are major problems. Various factors such as size, charge and
14 surface hydration of the liposomes play important roles here. Cellular membranes pose
15 another barrier to liposome uptake. The cationic liposomes show high transfection
16 efficiency, which can partly be attributed to interactions with negatively charged cell
17 membranes. The structure and properties of cationic lipids, lipoplex (see Glossary)
18 assembly and endocytosis of lipoplexes have recently been described in detail¹¹. The
19 internalisation of liposomes occurs most commonly by endocytosis, in which the genetic
20 material is subjected to degradation upon acidification in endolysosomes. Thus, the
21 efficiency of liposome uptake largely depends on their ability to escape the endosomal
22 environment and to deliver their DNA/RNA content safely into the cytosol. This is also
23 the reason why many research efforts have been directed towards enhancing endosomal

1 escape. Transfection efficiencies can be predicted from the structural phases of lipids and
2 the morphologies of lipoplexes. For example, studies have shown that the presence of a
3 non-bilayer-phase-preferring lipid, such as dioleoylphosphatidylethanolamine (DOPE) or
4 cholesterol, promotes transition of liquid crystalline phase (L^C_α) to inverted hexagonal
5 phase (H^C_{II}) and hence membrane fusion, indicating that increasing the weight fraction of
6 DOPE might result in higher transfection efficiencies ¹².

8 *Peptides for intracellular delivery*

9 Recently, peptides have been increasingly used with the aim to aid the intracellular
10 delivery of the genes. Tat peptide (TATp) is by far the most commonly used cell
11 penetrating peptide, or so-called protein transduction domain (PTD), and is derived from
12 the transcriptional activator protein encoded by human immunodeficiency virus type 1
13 (HIV-1). Its mechanism has recently been elucidated as macropinocytosis, a nonclathrin
14 noncaveolar endocytosis brought about by formation of large vacuoles that are generated
15 by actin filaments¹³. TATp-mediated delivery of liposomes and DNA has recently been
16 reviewed^{13, 14}. Octaarginine is another commonly used PTD that is thought to use cell
17 surface heparin sulfate proteoglycans as non-specific receptors for uptake. Octaarginine-
18 modified liposomes have been used for enhanced cellular uptake and controlled
19 intracellular trafficking of plasmid DNA¹⁵. Apart from cell penetration, peptides are also
20 being utilized for endosomal escape, which in turn results in higher transfection
21 efficiency. Another cell-penetrating peptide is GALA, (a 30-amino acid synthetic peptide
22 with a glutamic acid–alanine–leucine–alanine repeats), a fusogenic pH-sensitive peptide
23 developed by Szoka and co-workers that aids cytosolic delivery by facilitating the

1 disruption of endosomal membrane and release of DNA in cytoplasm. Kobayashi et al.
2 and Sasaki et al. demonstrated enhanced endosomal escape of macromolecules via
3 GALA and its derivatives^{16, 17}. While fusogenic peptides act upon acidification in
4 endosomes, it has been recently shown that a stearylated INF7 peptide derivative
5 enhanced gene expression in a fusion-independent manner and was able to rupture
6 artificial membranes, both at acidic and neutral pH, extending the time the liposomes
7 could escape endosomal degradation¹⁸. Once successful delivery of liposomes to the
8 cytosol has been accomplished, liposome-mediated gene delivery faces additional
9 obstacles, such as the requirement of intracellular trafficking to the nucleus and uptake
10 into the nucleus via the nuclear pore complexes. The potential of using nuclear
11 localisation signals (NLSs) for targeting to the nucleus has been studied by several
12 groups and it was found that the efficiency of nuclear targeting depended on the valency
13 (positive charges) associated with plasmid DNA and the number of NLS associated with
14 a cargo, such as plasmid DNA, proteins, liposomes and nanoparticles¹⁹. Different NLSs
15 will bind to different receptors on nuclear membranes, such as to importins²⁰ or farnesoid
16 X receptor (FXR)²¹, either directly or indirectly by forming complexes with other
17 cytoplasmic proteins. A significant increase in gene expression that was mediated by
18 liposomes and the means of using a NLS has been shown, both *in vitro* and *in vivo*^{20, 21}.
19 Attempts have also been made to utilize the biological responses against liposomes, such
20 as cytokine production, for their increased uptake. Tumor necrosis factor- α (TNF- α),
21 which is induced by lipoplexes, is known to activate transcription factor nuclear factor κ B
22 (NF- κ B), and NF- κ B upon activation can aid nuclear transfer of DNA. It has been

1 reported that if NF- κ B binding sequences are incorporated in plasmid DNA, lipoplex-
2 mediated transgene expression can be enhanced ²².

4 *Short term expression and toxicity related to liposomes*

5 Short-term expression following liposomal gene delivery constitutes a major problem in
6 clinical applications that require sustained levels of transgene expression over months
7 and years. Short-term expression is due to the cargo being either not integrated into the
8 host genome, or only unstably, and this limitation can be addressed with repeated doses
9 of the gene, a practice, which however is not always feasible and practical. Here, gene
10 delivery via release systems with an extended effect, such as tissue-engineered scaffolds,
11 presents the opportunity of controlled DNA release over a long period of time as required
12 for long-term expression. The toxicity of cationic lipids is another concern as these are
13 frequently inflammatory. This toxicity is dose-dependent and is based on to the exposure
14 of the liposome to and its interactions with immune cells. The use of tissue-engineered
15 scaffolds could address these issues as a topical delivery of liposomes via a tissue
16 scaffold would reduce their exposure to immune cells.

18 **Tissue-Engineered Scaffolds**

19 The view of tissue-engineered scaffolds as gene delivery systems is a relatively novel
20 concept. Initially, scaffolds were proposed for applications in tissue engineering and
21 considered solely as inert structural support for tissue repair and regeneration. Over the
22 last few years, this view has changed dramatically and scaffolds are no longer seen only
23 as dynamic tools for mimicking biological environments, but now are also regarded as

1 delivery vehicles for cells and/or bioactive agents. They provide a multitude of
2 advantages, such as safe profile, protection of cargo, and enhanced and extended gene
3 expression and the ability to control a localized delivery of cargo, as depicted in Figure 1.

4 5 *Tissue-engineered scaffolds as depots and controlled-release systems*

6 Tissue-engineered scaffolds can be designed in order to physically and/or chemically
7 control the release pattern of any incorporated bioactive agents. A controlled release of
8 DNA will not only lead to extended periods of gene and thus protein expression, but will
9 also minimize the risk of under- or over-dosing of the expressed protein. The major
10 advantage of using natural scaffolds, such as collagen and fibrin, in addition to their
11 safety profile, is their tunable degradation, which can be readily achieved either by
12 varying the concentration of monomers and/or crosslinking agents and thus controls the
13 long-term release of bioactive agents. Similar to extracellular matrix (ECM), fibrin-based
14 biomaterials could also act as temporary depots for the sustained release of substances²³,
15 which could be readily optimized by varying the concentrations of the fibrinogen and
16 thrombin components²⁴. The release profile of bioactive agents from collagen/gelatin
17 scaffolds can also be further optimized by appropriate choice of crosslinking agents, such
18 as microbial transglutaminase or *N*-ethyl-*N*-(3-diethylaminopropyl)-carbodiimide/*N*-
19 hydroxysuccinimide (EDC/NHS), as well as the degree of crosslinking.

20
21 As an alternative to natural scaffolds, synthetic scaffolds have also been suggested as
22 they are highly flexible in that they can be manufactured in any desired shape and size,
23 with a tightly defined architecture and relevant parameters such as porosity. Some of

1 these synthetic scaffolds, such as polylactic acid (PLA), also have the additional
2 advantage of a degradation within the body, which will only leave behind harmless
3 breakdown products such as lactic acid¹. By crosslinking of PLA with PEG, or by using
4 co-polymers such as poly(lactic-*co*-glycolic acid) (PLGA), their degradation in the body
5 can be further controlled¹.

6 7 *Need for further enhancement*

8 Although, as depicted in Figure 1, the enhanced and sustained localized gene delivery
9 that could be achieved via tissue-engineered scaffolds is certainly superior to that of
10 naked plasmid delivery, further enhancement is required for therapeutic benefit. Towards
11 this goal and as opposed to delivering naked plasmid DNA through scaffolds, a number
12 of researchers have utilized different transfection reagents such as liposomes to first
13 complex the DNA and to subsequently deliver these complexes via the scaffolds, as
14 outlined below.

15 16 **A combined liposome–scaffold approach**

17 As mentioned above, the combination of liposomal gene delivery systems with scaffold
18 technologies is now being considered as being complementary. Table 3 summarizes a
19 number of studies that have investigated tissue-engineered scaffold-mediated liposomal
20 gene delivery. The various aspects and intrinsic benefits offered by this combined
21 liposome-scaffold approach are discussed in detail below.

22 23 *Long-term expression*

1 By far the most important advantage of combining tissue-engineered scaffolds with
2 liposomal gene delivery is the possibility and flexibility of a well-controlled sustained
3 delivery. This allows to overcome an only short-term gene expression following
4 liposomal delivery, although the release kinetics of the used lipoplexes would depend on
5 various factors, such as their size and net charge, as well as their biomolecular and
6 chemical interactions.

7 The combination of tissue-engineered scaffolds with liposomes has already been utilized
8 for sustained delivery of drugs. For example, a single application of fibrin-enmeshed
9 tobramycin-bearing liposomes had a similar effect on reducing pseudomonas colonies
10 when treating pseudomonas keratitis compared to 24 hourly doses of fortified topical
11 tobramycin²⁵. Subsequently, a number of studies have described sustained release
12 systems using liposomes loaded with proteins or drugs and that had been incorporated in
13 fibrin²⁶⁻²⁹. The biomedical applications of collagen, including a combination of
14 liposomes with collagen for drug delivery, have been reviewed elsewhere³⁰.

15 The extended release of lipoplexes, and consequently the long-term expression of their
16 delivered genes, has been demonstrated by a number of groups³¹⁻³⁵. To achieve sustained
17 delivery, different approaches were possible. For example, lipoplexes could be merely
18 entrapped physically within the scaffolds by tailoring certain parameters, such as the
19 degree of crosslinking and pore sizes. Alternatively, lipoplexes were specifically bound
20 to components of the scaffolds. Recently, we described a fibrin-lipoplex system making
21 use of naturally-occurring interactions between liposomes and the fibrinogen components
22 of the scaffold, which obviated the need for chemical conjugation³².

Another approach for creating a sustained delivery system is the adsorption of lipoplexes on the surface of scaffolds³⁶⁻³⁸. To facilitate lipoplex adsorption, scaffold surfaces have been coated with various ECM proteins, and this has led to being able to transfect a higher number of cells, while at the same time reducing the amount of DNA required. Several other strategies have been developed to associate lipoplexes or DNA complexes with the scaffold surface, including the specific binding of complexes to the scaffold through biotin–avidin interaction, gelatin entrapment, or by nonspecific adsorption³⁶.

Maintaining lipoplex stability

Another major advantage of the combining liposomes with scaffolds is that this approach maintains lipoplex stability with a consequently prolonged bioactivity. An increased liposomal stability has been demonstrated in fibrin-encapsulated liposomes that were used as protein delivery system³⁹, as well as in biophysical studies of collagen-lipid interactions⁴⁰. The local delivery of lipoplexes from a biomaterial scaffold, such as fibronectin-coated PLG, could have the ability to maintain lipoplex stability and therefore could increase the number of transfected cells and transgene expression³⁴. In a spinal cord injury model, high transgene expression has been achieved by implanting fibronectin-coated-PLG bridges with multiple hollow channels that had been immobilised with lipoplexes³⁴. However, the fabrication of the scaffold can also adversely affect the stability of lipoplexes. Therefore, special processing techniques, such as cryopreparation or carbohydrate stabilization as well as mild processing conditions need to be adopted to avoid any detrimental effect on lipoplex stability, and thus the activity of incorporated DNA complexes⁴¹. On the other hand, if lipoplexes are immobilized on the surface of a

scaffold, the need for careful processing steps is obviated as the lipoplexes are immobilised after the scaffold fabrication.⁴².

Moderating lipoplex toxicity

Although considered safer than viral delivery systems, lipoplexes are frequently associated with some degree of toxicity, typically in the form of inflammatory responses.

The enhanced transgene expression observed via the combined liposome-scaffold approach reduces the required dose and this indirectly reduces dose-related toxicity.

However, the cellular toxicity seen in direct bolus delivery of lipoplexes has been shown to be reduced significantly when they are delivered via gene activated matrix (GAM)³¹.

This can be explained by the fact that, at any given time, only those lipoplexes that are released from and that are only a fraction of the total amount incorporated in the scaffold, are exposed to the immune cells. This apparent ‘fooling’ of the immune system helps to reduce the observed toxicity of lipoplexes. Another postulation that can explain the observed reduction in toxicity is that the specific interaction of cells with scaffold material such as fibrin can lead to suppression of the caspase pathway, which is involved in cell apoptosis and that of reactive oxygen species, which are typically activated by liposomes⁴³. Also, when compared to bolus delivery, this approach has been shown to transfect cells, which are otherwise hard to transfect such as primary cells, and with improved cellular viability³⁶. Thus, with regard to toxicity, embedding the lipoplexes within the scaffold appears a particular useful approach, whereas surface adsorption is beneficial in terms of flexibility of fabrication and stability. In addition, the possibility of

1 a localised therapy as afforded by the use of scaffolds significantly reduces the
2 occurrence of systemic toxicity.

4 *Multiple gene delivery and spatio-temporal patterning*

5 Combining liposomes with scaffolds also provides several additional advantages, such as
6 the possibility to deliver multiple genes simultaneously³², or to create spatial⁴⁴ and
7 temporal patterns of gene delivery. Recently, we demonstrated the successful
8 simultaneous delivery of two reporter genes by means of a fibrin-lipoplex model system
9 ³². Such a system might prove particularly useful in diseases in which multiple genes are
10 involved, or in which the local restoration of a specific gene function can result in
11 therapeutic benefit, e.g. the compromised wound healing seen in diabetes mellitus. In
12 most tissues in the body, a highly orchestrated spatio-temporal control of gene expression
13 is established, particularly in neural and vascular networks. Recently, spatially-patterned
14 expression of nerve growth factor (NGF) was achieved using lipoplexes that had been
15 immobilised in microfluidic networks of polydimethylsiloxane (PDMS) and this
16 patterned expression of NGF led to neurite outgrowth and guidance ⁴⁴. Another means to
17 control spatial gene expression, is to immobilize lipoplexes to specific regions of the
18 scaffold, which is the basis for transfected cell-arrays used in high-throughput functional
19 genomics studies³⁸. Here, patterned deposition of lipoplexes can be achieved by various
20 techniques, such as spotting, printing, pinning and microfluidics⁴⁵. Additionally, temporal
21 control over gene expression can be achieved in a number of ways, such as by layer-by-
22 layer assembly⁴⁶ of the scaffold with lipoplexes incorporated only in certain layers. Cell-
23 controlled temporal expression patterns are also possible⁴³, in which the lipoplexes are

1 confined within the scaffold, and only become available for transfection only upon cell-
2 mediated degradation of scaffold. Another approach could be to simply mixing polymer
3 scaffolds that have different degradation profiles⁴⁵ or to fabricating a complex scaffold
4 consisting of predetermined regions with different degradation rates, different porosity or
5 different density of “homing” agents, such as antibodies or peptide ligands. The success
6 of spatial patterning depends largely on the stability and activity of DNA complexes after
7 they have been deposited on or embedded in the scaffold, and thus, the differential
8 concentration achieved on the pattern as against the non-patterned region of the scaffold
9 ⁴⁵.

10 On the other hand, lipoplexes have also been shown to enhance the transfection
11 efficiency that can be achieved using only tissue-engineered scaffolds as demonstrated
12 for the delivery of lipoplexes based on fibrin-scaffolds based in skin wound healing ⁴⁷.
13 The authors of this study showed a significantly higher skin flap survival, when it was
14 treated with a fibrin-lipoplex system carrying vascular endothelial growth factor plasmid
15 (pVEGF) as compared to using a fibrin gel carrying pVEGF. The enhanced gene
16 expression upon liposome-scaffold delivery was synergistic and not merely additive.
17 Their claim could be substantiated by observations of six to seven-fold increase in
18 protein production compared to control levels as long as two weeks after treatment of rat
19 mesenchymal stem cells with a porous sponge-like collagen scaffold that had been
20 embedded with lipoplexes carrying glial cell line-derived neurotrophic factor (GDNF)
21 gene⁴⁸.

22
23 *Potential for clinical translation*

One of the most promising aspects of combining liposome with scaffold-based delivery is its potential for clinical translation in the near future. A range of tissue-engineered scaffolds have already been approved for human use and this list is ever-increasing and some relevant examples are summarized in Table 4. Currently, over a hundred clinical trials addressing liposomal gene delivery are underway and are at different phases of completion. Considering the advantageous regulatory status of tissue-engineered scaffolds and of liposomal approaches, a clinical realization of combined liposome-scaffold delivery could be anticipated within the next two decades.

Future perspectives

The full potential of a combined liposome-scaffold approach remains to be investigated as research to date has mainly focused on providing proof of concepts. It is anticipated that the future of a combined liposome-scaffold approach would be centered around two goals: making optimal use of the progress in individual fields and the understanding derived thereof, and utilizing and manipulating interactions between the liposomes and the scaffold material as depicted in Figure 2.

In particular, the versatility of liposomes has not yet been tested in the context of their inclusion into tissue engineered-scaffolds. The recent advances in liposomal gene delivery are yet to be applied in the combined approach. A recent study has already pointed out the need for focusing research on designing lipoplexes with the aim to increase the cellular internalization of DNA for enhancing gene delivery from scaffold surface ⁴⁹. It is therefore highly likely that the successful application of combination therapy will depend on advances in liposomal gene delivery with regard to targeted

1 delivery, enhanced intracellular trafficking and nuclear localization. The combined
2 strategy can also be approached from the scaffold using so called “smart” biomaterials,
3 such as stimuli-responsive polymers, or polymers that are cell interactive and based on
4 “click” chemistry. Shape memory polymers could be micropatterned with lipoplexes,
5 then compacted for ease of handling and for reaching the injury site, and upon
6 implantation would return to their original shape containing micropatterned lipoplexes.
7 This approach could be particular useful in areas of nerve regeneration, surgical sutures⁵⁰
8 and vascular stenting^{51, 52}. *In situ* gelling systems with lower critical solution temperature
9 (see Glossary) at body temperature could be employed to carry lipoplexes, which after
10 application to wounds would form a gel scaffold and subsequently release lipoplexes in a
11 sustained manner. Also, research in the field of whole tissue organ regeneration can be
12 geared up through micropatterned lipoplexes in 3-D scaffolds for the creation of a highly
13 controlled spatio-temporal gene expression, mimicking the natural embryonic
14 development. A thorough understanding of interactions between liposomes and the
15 scaffold might pave the way towards fathoming the release mechanisms and adding
16 additional levels of control.

20 *References*

- 21
- 22 1. Agarwal, A., and Mallapragada, S.K. (2008) Synthetic sustained gene delivery
23 systems. *Curr Top Med Chem* 8, 311-310
- 24 2. Banerjee, R. (2001) Liposomes: applications in medicine. *J Biomater Appl* 16, 3-
25 21
- 26 3. Samad, A., *et al.* (2007) Liposomal drug delivery systems: an update review. *Curr*
27 *Drug Deliv* 4, 297-305

- 1 4. Kale, A.A., and Torchilin, V.P. (2007) Enhanced transfection of tumor cells in
2 vivo using "Smart" pH-sensitive TAT-modified pegylated liposomes. *J Drug Target* 15,
3 538-545
- 4 5. Leong-Poi, H., *et al.* (2007) Therapeutic arteriogenesis by ultrasound-mediated
5 VEGF165 plasmid gene delivery to chronically ischemic skeletal muscle. *Circ Res* 101,
6 295-303
- 7 6. Zheng, X., *et al.* (2009) Preparation and characterization of magnetic cationic
8 liposome in gene delivery. *Int J Pharm* 366, 211-217
- 9 7. Wu, G., *et al.* (2008) Remotely triggered liposome release by near-infrared light
10 absorption via hollow gold nanoshells. *J Am Chem Soc* 130, 8175-8177
- 11 8. Hanzlikova, M., *et al.* (2009) The role of PEI structure and size in the
12 PEI/liposome-mediated synergism of gene transfection. *Plasmid* 61, 15-21
- 13 9. Lampela, P., *et al.* (2004) Synergism in gene delivery by small PEIs and three
14 different nonviral vectors. *Int J Pharm* 270, 175-184
- 15 10. Lee, C.H., *et al.* (2003) Synergistic effect of polyethylenimine and cationic
16 liposomes in nucleic acid delivery to human cancer cells. *Biochim Biophys Acta* 1611,
17 55-62
- 18 11. Wasungu, L., and Hoekstra, D. (2006) Cationic lipids, lipoplexes and intracellular
19 delivery of genes. *J Control Release* 116, 255-264
- 20 12. Ma, B., *et al.* (2007) Lipoplex morphologies and their influences on transfection
21 efficiency in gene delivery. *J Control Release* 123, 184-194
- 22 13. Torchilin, V.P. (2008) Cell penetrating peptide-modified pharmaceutical
23 nanocarriers for intracellular drug and gene delivery. *Biopolymers* 90, 604-610
- 24 14. Torchilin, V.P. (2008) Tat peptide-mediated intracellular delivery of
25 pharmaceutical nanocarriers. *Adv Drug Deliv Rev* 60, 548-558
- 26 15. Khalil, I.A., *et al.* (2008) Octaarginine-modified liposomes: enhanced cellular
27 uptake and controlled intracellular trafficking. *Int J Pharm* 354, 39-48
- 28 16. Kobayashi, S., *et al.* (2009) Cytosolic Targeting of Macromolecules Using a pH-
29 Dependent Fusogenic Peptide in Combination with Cationic Liposomes. *Bioconjug Chem*
- 30 17. Sasaki, K., *et al.* (2008) An artificial virus-like nano carrier system: enhanced
31 endosomal escape of nanoparticles via synergistic action of pH-sensitive fusogenic
32 peptide derivatives. *Anal Bioanal Chem* 391, 2717-2727
- 33 18. El-Sayed, A., *et al.* (2009) Enhanced gene expression by a novel stearylated INF7
34 peptide derivative through fusion independent endosomal escape. *J Control Release* 138,
35 160-167
- 36 19. Sung, M., *et al.* (2006) The importance of valency in enhancing the import and
37 cell routing potential of protein transduction domain-containing molecules. *Biochim*
38 *Biophys Acta* 1758, 355-363
- 39 20. Vaysse, L., *et al.* (2006) Nuclear-targeted minicircle to enhance gene transfer with
40 non-viral vectors in vitro and in vivo. *J Gene Med* 8, 754-763
- 41 21. Liu, F., *et al.* (2007) Novel nonviral vectors target cellular signaling pathways:
42 regulated gene expression and reduced toxicity. *J Pharmacol Exp Ther* 321, 777-783
- 43 22. Kuramoto, T., *et al.* (2006) Use of lipoplex-induced nuclear factor-kappaB
44 activation to enhance transgene expression by lipoplex in mouse lung. *J Gene Med* 8, 53-
45 62

23. Morton, T.J., *et al.* (2009) Controlled release of substances bound to fibrin-anchors or of DNA. *Drug Deliv* 16, 102-107
24. Breen, A., *et al.* (2006) A Stereological Based Approach to Characterise Healing in the Alloxan Induced Diabetic Rabbit Ear Ulcer. In *Department of Mechanical and Biomedical Engineering*, National Univeristy of Ireland, Galway
25. Frucht-Perry, J., *et al.* (1992) Fibrin-enmeshed tobramycin liposomes: single application topical therapy of Pseudomonas keratitis. *Cornea* 11, 393-397
26. Meyenburg, S., *et al.* (2000) Fibrin encapsulated liposomes as protein delivery system Studies on the in vitro release behaviour. *J Control Release* 69, 159-168
27. Giannoni, P., and Hunziker, E.B. (2003) Release kinetics of transforming growth factor-beta1 from fibrin clots. *Biotechnol Bioeng* 83, 121-123
28. Chung, T.W., *et al.* (2006) A fibrin encapsulated liposomes-in-chitosan matrix (FLCM) for delivering water-soluble drugs. Influences of the surface properties of liposomes and the crosslinked fibrin network. *Int J Pharm* 311, 122-129
29. Wang, S.S., *et al.* (2008) Liposomes/chitosan scaffold/human fibrin gel composite systems for delivering hydrophilic drugs--release behaviors of tirofiban in vitro. *Drug Deliv* 15, 149-157
30. Lee, C.H., *et al.* (2001) Biomedical applications of collagen. *Int J Pharm* 221, 1-22
31. Winn, S.R., *et al.* (2005) Non-viral-mediated gene therapy approaches for bone repair. *Orthod Craniofac Res* 8, 183-190
32. Kulkarni, M., *et al.* (2009) Fibrin-lipoplex system for controlled topical delivery of multiple genes. *Biomacromolecules* 10, 1650-1654
33. Capito, R.M., and Spector, M. (2007) Collagen scaffolds for nonviral IGF-1 gene delivery in articular cartilage tissue engineering. *Gene Ther* 14, 721-732
34. De Laporte, L., *et al.* (2009) Local gene delivery from ECM-coated poly(lactide-co-glycolide) multiple channel bridges after spinal cord injury. *Biomaterials* 30, 2361-2368
35. Whittlesey, K.J., and Shea, L.D. (2006) Nerve growth factor expression by PLG-mediated lipofection. *Biomaterials* 27, 2477-2486
36. Bengali, Z., *et al.* (2005) Gene delivery through cell culture substrate adsorbed DNA complexes. *Biotechnol Bioeng* 90, 290-302
37. Rea, J.C., *et al.* (2009) Self-assembling peptide-lipoplexes for substrate-mediated gene delivery. *Acta Biomater* 5, 903-912
38. Bengali, Z., and Shea, L.D. (2005) Gene Delivery by Immobilization to Cell-Adhesive Substrates. *MRS Bull* 30, 659-662
39. Meyenburg, S., *et al.* (2000) Fibrin encapsulated liposomes as protein delivery system. Studies on the in vitro release behavior. *J Control Release* 69, 159-168
40. Mady, M.M. (2007) Biophysical studies on collagen-lipid interaction. *J Biosci Bioeng* 104, 144-148
41. Pannier, A.K., and Shea, L.D. (2004) Controlled release systems for DNA delivery. *Mol Ther* 10, 19-26
42. Houchin-Ray, T., *et al.* (2007) Patterned PLG substrates for localized DNA delivery and directed neurite extension. *Biomaterials* 28, 2603-2611
43. Lei, P., *et al.* (2009) Cell-controlled and spatially arrayed gene delivery from fibrin hydrogels. *Biomaterials* 30, 3790-3799

- 1 44. Houchin-Ray, T., *et al.* (2009) Spatially patterned gene expression for guided
2 neurite extension. *J Neurosci Res* 87, 844-856
- 3 45. De Laporte, L., and Shea, L.D. (2007) Matrices and scaffolds for DNA delivery in
4 tissue engineering. *Adv Drug Deliv Rev* 59, 292-307
- 5 46. Yamauchi, F., *et al.* (2005) Layer-by-layer assembly of poly(ethyleneimine) and
6 plasmid DNA onto transparent indium-tin oxide electrodes for temporally and spatially
7 specific gene transfer. *Langmuir* 21, 8360-8367
- 8 47. Michlits, W., *et al.* (2007) Fibrin-embedded administration of VEGF plasmid
9 enhances skin flap survival. *Wound Repair Regen* 15, 360-367
- 10 48. Bolliet, C., *et al.* (2008) Non-viral delivery of the gene for glial cell line-derived
11 neurotrophic factor to mesenchymal stem cells in vitro via a collagen scaffold. *Tissue*
12 *Eng Part C Methods* 14, 207-219
- 13 49. Bengali, Z., *et al.* (2009) Efficacy of immobilized polyplexes and lipoplexes for
14 substrate-mediated gene delivery. *Biotechnol Bioeng* 102, 1679-1691
- 15 50. Lamprakos, A.A., *et al.* (2009) Biomechanical testing of a shape memory alloy
16 suture in a meniscal suture model. *Arthroscopy* 25, 632-638
- 17 51. Ajili, S.H., *et al.* (2009) Polyurethane/polycaprolactane blend with shape memory
18 effect as a proposed material for cardiovascular implants. *Acta Biomater* 5, 1519-1530
- 19 52. Baer, G.M., *et al.* (2009) Thermomechanical properties, collapse pressure, and
20 expansion of shape memory polymer neurovascular stent prototypes. *J Biomed Mater Res*
21 *B Appl Biomater* 90, 421-429
- 22 53. Wilson, A., *et al.* (2005) Targeted delivery of oligodeoxynucleotides to mouse
23 lung endothelial cells in vitro and in vivo. *Mol Ther* 12, 510-518
- 24 54. Sato, A., *et al.* (2007) Small interfering RNA delivery to the liver by intravenous
25 administration of galactosylated cationic liposomes in mice. *Biomaterials* 28, 1434-1442
- 26 55. Li, S.D., and Huang, L. (2006) Surface-modified LPD nanoparticles for tumor
27 targeting. *Ann N Y Acad Sci* 1082, 1-8
- 28 56. Lu, Y., *et al.* (2007) Development of an antigen-presenting cell-targeted DNA
29 vaccine against melanoma by mannoseylated liposomes. *Biomaterials* 28, 3255-3262
- 30 57. Zhang, Y., *et al.* (2008) Lysosomal enzyme replacement of the brain with
31 intravenous non-viral gene transfer. *Pharm Res* 25, 400-406
- 32 58. Peer, D., *et al.* (2008) Systemic leukocyte-directed siRNA delivery revealing
33 cyclin D1 as an anti-inflammatory target. *Science* 319, 627-630
- 34 59. Zhang, H., *et al.* (2008) Dynamic imaging of arginine-rich heart-targeted vehicles
35 in a mouse model. *Biomaterials* 29, 1976-1988
- 36 60. Kim, K.S., *et al.* (2008) Targeted gene therapy of LS174 T human colon
37 carcinoma by anti-TAG-72 immunoliposomes. *Cancer Gene Ther* 15, 331-340
- 38 61. Li, S.D., *et al.* (2008) Efficient oncogene silencing and metastasis inhibition via
39 systemic delivery of siRNA. *Mol Ther* 16, 942-946
- 40 62. Tagalakos, A.D., *et al.* (2008) A receptor-targeted nanocomplex vector system
41 optimized for respiratory gene transfer. *Mol Ther* 16, 907-915
- 42 63. Chono, S., *et al.* (2008) An efficient and low immunostimulatory nanoparticle
43 formulation for systemic siRNA delivery to the tumor. *J Control Release* 131, 64-69
- 44 64. Ko, Y.T., *et al.* (2009) Gene delivery into ischemic myocardium by double-
45 targeted lipoplexes with anti-myosin antibody and TAT peptide. *Gene Ther* 16, 52-59

- 1 65. Ko, Y.T., *et al.* (2009) Liposome encapsulated polyethylenimine/ODN polyplexes
2 for brain targeting. *J Control Release* 133, 230-237
- 3 66. Kolb, H.C., *et al.* (2001) Click Chemistry: Diverse Chemical Function from a
4 Few Good Reactions. *Angew Chem Int Ed Engl* 40, 2004-2021
- 5
- 6

Table 1 : Stimuli-responsive liposomes: prominent recent studies

Stimuli-responsiveness in liposomes	Additional modifications	<i>In vitro / in vivo</i>	Applications	References
pH-sensitive liposomes				
Hydrazone	PEG on TATp liposomes via pH/ non-pH sensitive bonds	<i>In vitro</i> and <i>in vivo</i>	Tumor specific intracellular gene delivery	4
Ultrasound-sensitive liposomes				
Lipidshelled decafluorobutane microbubbles	-	<i>In vivo</i>	Therapeutic arteriogenesis	5
Magnetic field-sensitive liposomes				
Magnetite in cationic liposomes	Varying concentrations of magnetite	<i>In vitro</i> and <i>in vivo</i>	Enhanced gene transfer under influence of a magnetic field	6
Hollow gold nanoshells (near infrared light)	Different coupling methods, hollow gold nanoshells tethering, encapsulation or in free suspension outside the liposomes	Light-sensitive liposomes <i>In vitro</i>	Remote triggering of liposome release by near infrared light	7

Table 2: Targeted liposomes in gene delivery, prominent recent examples

Targeting moiety	Targeted tissue / Cells / Receptors	Application	Reference
Endothelium-specific antibody (273-34A)	Mouse lung endothelial cells	Targeted delivery of oligodeoxynucleotides	53
Galactosylated cationic liposomes	Liver / parenchymal cells	siRNA delivery	54
DSPE-PEG-anisamide	Human lung cancer cells	Liposome-polycation-DNA nanoparticles for tumor targeting	55
Mannosylated cationic liposomes	Melanoma/ Mannose receptors	DNA vaccination	56
Monoclonal antibody: rat 8D3	Mouse transferrin receptor	Gene delivery to Brain	57
Monoclonal antibody: FIB504	Gut mononuclear leukocytes/ B ₇ integrins	Systemic leukocyte-directed siRNA delivery	58
CRPPR peptide	Heart endothelium	Targeting of heart and dynamic imaging	59
Fab' fragments of recombinant humanised monoclonal antibody, HuCC49	TAG-72-overexpressing cancer cells	Systemic gene delivery to human colon cancer cells	60
DSPE-PEG2000-anisamide	B16F10 cells / Sigma receptor	siRNA delivery to metastatic tumors	61
K16GACSERSMNFCG	Lung/human airway epithelial cell lines/(ICAM-1)	Cystic fibrosis gene therapy	62
DSPE-PEG-anisamide	Sigma receptor over-expressed in the B16F10 melanoma cells	siRNA delivery to tumors	63
Monoclonal antibody: 2G4	Myocardium/ myosin	Gene delivery to ischemic myocardium	64
Monoclonal antibody: 8D3	Brain/ transferrin receptor	Targeted delivery to brain	65

Table 3: Combined liposome-scaffold approach for gene delivery

Scaffold/ Substrate	Liposomes	DNA	Application	References
Serum-coated tissue culture polystyrene	Lipofectamine™ 2000	Plasmid- luciferase/ EGFP	Substrate mediated delivery	36
Porous poly (D,L-lactide) disks	FuGene® 6 lipophilic transfection reagent; 20 mM DOTAP; cholesterol (1:1) liposome	Plasmid- GFP	Bone repair	31
PLG matrices	Lipofectamine™ 2000	Plasmid- luciferase/ β -galactosidase/NGF/ NGF-GFP dual expression	Nerve regeneration	35
Type II collagen glycosaminoglycan scaffolds	GenePORTER® Reagent	Plasmid- insulin-like growth factor (IGF)-I	Cartilage repair	33
Fibrin	Lipofectamine™ and Plus Reagent	Plasmid- VEGF	Wound healing	47
Collagen	GenePORTER® Reagent	Plasmid- GDNF	Brain injury	48
Tissue culture polystyrene	Lipofectamine™ 2000	Plasmid- EGFP-luciferase	Substrate mediated delivery	49
Polystyrene plate	Lipofectamine™	Plasmid- luciferase	Substrate mediated delivery	37
Fibrin	Lipofectin ®Reagent	Plasmid- EGFP; luciferase + β -galactosidase	Simultaneous delivery of multiple genes to wound bed	32
ECM coated Multiple channel PLG bridges	TransFast™ Transfection Reagent	Plasmid- firefly luciferase and β -galactosidase	Spinal cord injury	34
Polydimethylsiloxane cured on patterned molds using photolithography	Lipofectamine™ 2000	Plasmid- EGFP + luciferase; NGF	Nerve repair	44

Table 4: Examples of tissue-engineered scaffolds approved for human use

Major component	Clinical use	Market name	Marketed by
Collagen	Skin repair	TransCyte	Advanced Biohealing (http://www.advancedbiohealing.com/)
		Apligraf	Organogenesis (http://www.organogenesis.com/)
		Dermagraft	Advanced Biohealing (http://www.advancedbiohealing.com/)
		INTEGRA dermal regeneration template	Integra Lifesciences (http://www.integra-ls.com/home/)
	Bone repair	Infuse bone graft	Medtronic (http://www.medtronic.com/)
		OP-1	Stryker (http://www.stryker.com/en-us/index.htm)
		VITOSS Scaffold FOAM	Orthovita and Kensey Nash (http://www.orthovita.com/) http://www.kenseynash.com/index.asp)
		FortrOss	Pioneer Surgical (http://www.pioneersurgical.com/)
		BioSet-RTI	Pioneer Surgical and Regeneration Technologies (http://www.pioneersurgical.com/) http://www.rtix.com/)
	Nerve conduit Cartilage repair	NeuraGen	Integra (http://www.integra-ls.com/home/)
		Menaflex	Regenbiologics (http://www.regenbio.com/usa/en/)
		CaReS	Arthro Kinetics (http://www.arthro-kinetics.com/)
Fibrin	Sealant for wound management	TISSEEL	Baxter International (http://www.baxter.com/)
Gelatin	Bone repair	Regenafil	Exactech (http://www.exac.com/)

Glossary:

Click Chemistry: an approach described by K. Barry Sharpless wherein substances are generated by joining small units together with heteroatom links (C- X- C). The reaction to be termed as click chemistry based, certain criteria must be met: the reaction must be modular, wide in scope, give very high yields, generate only inoffensive byproducts that can be removed by non-chromatographic methods and be stereoscopic⁶⁶

Lipoplexes: complexes consisting of liposomes and nucleic acids. Cationic lipids, on account of their positive charge, readily complex with negatively charged nucleic acids. Nucleic acids can be compacted in these particles. Lipoplexes facilitate the entry of nucleic acids within cells and protect their degradation by nucleases.

Lower critical solution temperature: temperature below which a mixture is miscible in all proportions

Tissue engineered scaffolds: fundamental components of tissue engineering, made up of natural or synthetic macromolecules. Scaffolds are 3-D macrostructures and can take a variety of architectural forms such as gels, hydrogels, foams or sponges, with defined parameters such as pore size, mechanical strength and degradation rate.

Figures Legends:

Figure 1. Schematic depiction of the role of tissue-engineered scaffolds in gene delivery. Tissue-engineered scaffolds can be employed either as reservoirs, or as sustained delivery systems. If they are used as reservoirs, the host tissue will integrate with the scaffold material and the contents of the scaffolds will exhibit their intended function in the context of the host tissue. In sustained delivery systems, the contents of the scaffolds are delivered as and when the scaffold material degrades. This results in long-term gene expression when compared with delivery by lipoplexes alone. As depicted in the graph shown below, tissue-engineered scaffold-mediated sustained gene delivery enhanced gene expression and a synergistic effect is observed when tissue-engineered scaffolds delivered lipoplexes (yellow curve) as opposed to naked plasmids (purple curve).

Figure 2. Schematic illustration of potential future developments of tissue-engineered scaffold-mediated liposomal delivery. Breakthroughs in the near future will most likely be based on the full utilization and application of recent advances in individual biomaterials, including stimuli-responsive materials, shape memory polymers, and interactive polymers. Advancements in liposome technology, such as the development of stimuli-responsive and functionalized formulations, will also contribute to further progress together with the advent of innovative release strategies.

Figure 1
Click here to download high resolution image

Figure 2
Click here to download high resolution image